-
02 June 2026 12:42:50
- Source: Sharecast
Hikma Pharmaceuticals PLC - LTIP and EIP Vesting
LONDON, 2 June 2026: Hikma Pharmaceuticals PLC (LSE: HIK) (Nasdaq Dubai: HIK) ("Hikma") (LEI: 549300BNS685UXH4JI75) announces that the following Persons Discharging Managerial Responsibility ("PDMRs") have received shares as a result of the vesting of their conditional share awards which were granted on 30 May 2023 under the 2023 Long-Term Incentive Plan ("LTIP") and 2014 Executive Incentive Plan ("EIP") Element C.
Notification and public disclosure of transactions by Persons Discharging Managerial Responsibilities
Said Darwazah
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
||
|
a) |
Name |
Said Darwazah |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
Chief Executive Officer |
|
|
b) |
Initial notification /Amendment |
Initial notification |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
Hikma Pharmaceuticals PLC |
|
|
b) |
LEI |
549300BNS685UXH4JI75 |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 |
|
|
b) |
Nature of the transaction |
Shares acquired from the vesting of conditional awards under the LTIP and EIP. All shares were retained. |
|
|
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
Nil |
LTIP Award: 91,812 |
||
|
Nil |
EIP Award, Element C: 19,761 |
||
|
d) |
Aggregated information |
Price(s): nil Volume(s): 111,573 |
|
|
e) |
Date of the transaction |
1 June 2026 |
|
|
f) |
Place of the transaction |
London Stock Exchange (XLON) |
|
Mazen Darwazah
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
||
|
a) |
Name |
Mazen Darwazah |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
Executive Vice Chairman and Deputy CEO, MENA |
|
|
b) |
Initial notification /Amendment |
Initial notification |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
Hikma Pharmaceuticals PLC |
|
|
b) |
LEI |
549300BNS685UXH4JI75 |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 |
|
|
b) |
Nature of the transaction |
Shares acquired from the vesting of conditional awards under the LTIP and EIP. All shares were retained. |
|
|
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
Nil |
LTIP Award: 72,763 |
||
|
Nil |
EIP Award, Element C: 20,650 |
||
|
d) |
Aggregated information |
Price(s): nil Volume(s): 93,413 |
|
|
e) |
Date of the transaction |
1 June 2026 |
|
|
f) |
Place of the transaction |
London Stock Exchange (XLON) |
|
Khalid Nabilsi
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
||
|
a) |
Name |
Khalid Nabilsi |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
Deputy CEO, North America and Europe |
|
|
b) |
Initial notification /Amendment |
Initial notification |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
Hikma Pharmaceuticals PLC |
|
|
b) |
LEI |
549300BNS685UXH4JI75 |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 |
|
|
b) |
Nature of the transaction |
Shares acquired from the vesting of conditional awards under the LTIP and EIP. All shares were retained. |
|
|
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
Nil |
LTIP Award: 51,650 |
||
|
Nil |
EIP Award, Element C: 22,209 |
||
|
d) |
Aggregated information |
Price(s): nil Volume(s): 73,859 |
|
|
e) |
Date of the transaction |
1 June 2026 |
|
|
f) |
Place of the transaction |
London Stock Exchange (XLON) |
|
Bassam Kanaan
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
||
|
a) |
Name |
Bassam Kanaan |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
PDMR |
|
|
b) |
Initial notification /Amendment |
Initial notification |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
Hikma Pharmaceuticals PLC |
|
|
b) |
LEI |
549300BNS685UXH4JI75 |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 |
|
|
b) |
Nature of the transaction |
Shares acquired from the vesting of conditional awards under the LTIP and EIP. All shares were retained. |
|
|
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
Nil |
LTIP Award: 52,640 |
||
|
Nil |
EIP Award, Element C: 20,982 |
||
|
d) |
Aggregated information |
Price(s): nil Volume(s): 73,622 |
|
|
e) |
Date of the transaction |
1 June 2026 |
|
|
f) |
Place of the transaction |
London Stock Exchange (XLON) |
|
Hussein Arkhagha
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
||
|
a) |
Name |
Hussein Arkhagha |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
PDMR |
|
|
b) |
Initial notification /Amendment |
Initial notification |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
Hikma Pharmaceuticals PLC |
|
|
b) |
LEI |
549300BNS685UXH4JI75 |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 |
|
|
b) |
Nature of the transaction |
Shares acquired from the vesting of conditional awards under the LTIP and EIP. All shares were retained. |
|
|
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
Nil |
LTIP Award: 28,631 |
||
|
Nil |
EIP Award, Element C: 12,406 |
||
|
d) |
Aggregated information |
Price(s): nil Volume(s): 41,037 |
|
|
e) |
Date of the transaction |
1 June 2026 |
|
|
f) |
Place of the transaction |
London Stock Exchange (XLON) |
|
Susan Ringdal
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
||
|
a) |
Name |
Susan Ringdal |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
PDMR |
|
|
b) |
Initial notification /Amendment |
Initial notification |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
Hikma Pharmaceuticals PLC |
|
|
b) |
LEI |
549300BNS685UXH4JI75 |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 |
|
|
b) |
Nature of the transaction |
Shares acquired from the vesting of conditional awards under the LTIP and EIP. |
|
|
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
Nil |
LTIP Award: 26,558 |
||
|
Nil |
EIP Award, Element C: 11,664 |
||
|
d) |
Aggregated information |
Price(s): nil Volume(s): 38,222 |
|
|
e) |
Date of the transaction |
1 June 2026 |
|
|
f) |
Place of the transaction |
London Stock Exchange (XLON) |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 |
|
|
b) |
Nature of the transaction |
All shares sold following the vesting of conditional awards under the LTIP and EIP. |
|
|
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
£14.49 |
LTIP Award: 26,558 |
||
|
£14.49 |
EIP Award, Element C: 11,664 |
||
|
d) |
Aggregated information |
Price(s): £14.49 Volume(s): 38,222 Total(s): £553,748.83 |
|
|
e) |
Date of the transaction |
1 June 2026 |
|
|
f) |
Place of the transaction |
London Stock Exchange (XLON) |
|
Helen Middlemist
Group Company Secretary
+44 (0)20 7399 2760
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.